Compare MEG & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MEG | ABUS |
|---|---|---|
| Founded | 2012 | 2005 |
| Country | United States | United States |
| Employees | 3500 | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 930.8M | 848.8M |
| IPO Year | 2020 | 2008 |
| Metric | MEG | ABUS |
|---|---|---|
| Price | $22.14 | $4.56 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $35.25 | $5.00 |
| AVG Volume (30 Days) | 266.4K | ★ 1.2M |
| Earning Date | 05-05-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 93.69 | 55.26 |
| EPS | N/A | ★ 0.87 |
| Revenue | ★ $830,538,000.00 | $14,083,000.00 |
| Revenue This Year | $5.41 | N/A |
| Revenue Next Year | $7.19 | $239.71 |
| P/E Ratio | ★ N/A | $5.28 |
| Revenue Growth | 19.26 | ★ 128.21 |
| 52 Week Low | $19.38 | $3.04 |
| 52 Week High | $32.00 | $5.10 |
| Indicator | MEG | ABUS |
|---|---|---|
| Relative Strength Index (RSI) | 52.09 | 57.10 |
| Support Level | $20.80 | $4.16 |
| Resistance Level | $23.48 | $4.60 |
| Average True Range (ATR) | 0.79 | 0.18 |
| MACD | 0.13 | 0.04 |
| Stochastic Oscillator | 88.92 | 67.81 |
Montrose Environmental Group Inc is an environmental services company. The firm's operating segments are Assessment, Permitting and Response, Measurement and Analysis, and Remediation and Reuse. Through its Assessment, Permitting, and Response segment, the company provides scientific advisory and consulting services to support environmental assessments, environmental emergency response, and environmental audits and permits. Measurement and Analysis include test and analysis of air, water, and soil to determine concentrations of contaminants whereas, the Remediation and Reuse segment provide clients with engineering, design, implementation, operations and maintenance services, to treat contaminated water, and soil remediation. The company derives maximum revenue from United States.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.